Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Oncogenic receptor tyrosine kinases including anaplastic lymphoma kinase (ALK) are implicated in numerous solid and hematologic cancers. ALK mutations are reported in an estimated 9% of neuroblastoma and recent reports indicate that the percentage of ALK-positive cases increases in the relapsed pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Alam, Muhammad Wasi, Borenäs, Marcus, Lind, Dan E., Cervantes-Madrid, Diana, Umapathy, Ganesh, Palmer, Ruth H., Hallberg, Bengt
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625372/
https://ncbi.nlm.nih.gov/pubmed/31334113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00579
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars